Isidro Salusky

Q: What Schools Are Affiliated With Isidro Salusky

Isidro Salusky is affiliated with the following schools: University of Buenos Aires, University of California, Los Angeles, Massachusetts General Hospital

Isidro Salusky's AcademicInfluence.com Rankings

Isidro Salusky

Medical

#1670

World Rank

#2034

Historical Rank

Nephrology

#15

World Rank

#15

Historical Rank

medical Degrees

Download Badge

Medical

Isidro Salusky's Degrees

Doctorate Medicine University of Buenos Aires

Why Is Isidro Salusky Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Isidro B. Salusky is an American nephrologist. Biography Salusky obtained his M.D. degree from the National University of Buenos Aires in Argentina and completed a residency in Buenos Aires. He completed a fellowship in pediatric nephrology in Paris, as well as research and clinical fellowships in Los Angeles. Salusky became a Distinguished Professor of Pediatrics and Chief, Pediatric Nephrology at the Ronald Reagan UCLA Medical Center.

(See a Problem?)

Isidro Salusky's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. (2000) (2752)
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. (2003) (2521)
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. (2006) (895)
Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. (2009) (324)
Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. (1994) (313)
A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. (1999) (277)
Suppression of iron-regulatory hepcidin by vitamin D. (2014) (258)
Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. (2009) (240)
Chronic kidney disease, hypovitaminosis D, and mortality in the United States. (2009) (217)
Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. (1994) (200)
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. (2010) (181)
Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. (1993) (175)
Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. (2004) (173)
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25‐dihydroxyvitamin D in human monocytes (2013) (164)
Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. (1988) (162)
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. (2011) (159)
FGF-23: More Than a Regulator of Renal Phosphate Handling? (2010) (159)
Hypovitaminosis D in chronic kidney disease. (2008) (158)
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. (2009) (148)
Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. (1998) (146)
Effect of various protein diets on growth, renal function, and survival of uremic rats. (1979) (145)
Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. (2012) (139)
Bone disease in children and adolescents undergoing successful renal transplantation. (1998) (139)
Nutritional status of children undergoing continuous ambulatory peritoneal dialysis. (1983) (134)
Early skeletal and biochemical alterations in pediatric chronic kidney disease. (2012) (134)
Disordered FGF23 and mineral metabolism in children with CKD. (2014) (122)
Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. (2003) (121)
K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease: Work group membership (2005) (118)
Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. (1993) (118)
Peritoneal membrane transport function in children receiving long-term dialysis. (1996) (115)
Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. (1998) (113)
Chronic kidney disease mineral and bone disorder in children (2007) (104)
Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. (1991) (103)
Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. (2010) (97)
Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. (2016) (94)
The consequences of chronic kidney disease on bone metabolism and growth in children. (2012) (89)
Value of the new bone classification system in pediatric renal osteodystrophy. (2010) (88)
Cardiovascular calcification in end-stage renal disease. (2002) (88)
Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow (2017) (85)
The pediatric nephrologist's dilemma: growth after renal transplantation and its interaction with age as a possible immunologic variable. (1987) (84)
Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. (1986) (83)
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. (2005) (82)
Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. (1989) (80)
Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. (1998) (78)
Growth Retardation in Children with Chronic Renal Failure (1999) (77)
Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. (1984) (76)
Improved cadaveric renal transplant outcome in children (2004) (75)
Adynamic renal osteodystrophy: is there a problem? (2001) (74)
Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. (2018) (70)
Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. (1991) (70)
Continuous ambulatory peritoneal dialysis in children. (1982) (70)
Cardiovascular MRI with ferumoxytol. (2016) (66)
Surgical management of peritoneal dialysis catheters in children: five-year experience with 1,800 patient-month follow-up. (1986) (65)
The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). (2010) (61)
Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. (2016) (60)
Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. (1998) (60)
"High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. (1987) (60)
FGF23 and Left Ventricular Hypertrophy in Children with CKD. (2018) (59)
Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. (2003) (59)
Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. (1990) (58)
Technical approach to iliac crest biopsy. (2008) (58)
High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort (2015) (54)
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. (2007) (52)
Prolonged renal survival and stunting, with protein-deficient diets in experimental uremia. Reversal of these effects by addition of essential amino acids. (1981) (52)
Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. (1995) (51)
Sevelamer hydrochloride: an effective phosphate binder in dialyzed children (2003) (51)
Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. (2016) (49)
Five years' experience with continuous ambulatory or continuous cycling peritoneal dialysis in children. (1987) (48)
Protein and amino acid metabolism in posterior hemicorpus of acutely uremic rats. (1983) (48)
A position statement on kidney disease from powdered infant formula-based melamine exposure in Chinese infants (2009) (47)
Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? (2011) (47)
FGF23 protein expression in coronary arteries is associated with impaired kidney function. (2014) (47)
Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. (2002) (46)
A new era in phosphate binder therapy: what are the options? (2006) (44)
Control of serum phosphorus in uremia. (1989) (44)
Calcium-regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism. (1995) (44)
Four‐dimensional, multiphase, steady‐state imaging with contrast enhancement (MUSIC) in the heart: A feasibility study in children (2015) (43)
Hyperlipidemia in pediatric patients undergoing peritoneal dialysis (1988) (43)
MRI with ferumoxytol: A single center experience of safety across the age spectrum (2016) (43)
Vascular access complications in long-term pediatric hemodialysis patients (2008) (43)
MR imaging of bone marrow in children. (1986) (43)
Calcium-regulated parathyroid hormone secretion in adynamic renal osteodystrophy. (1995) (43)
Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. (2000) (42)
Gram-negative peritonitis in children undergoing long-term peritoneal dialysis. (2008) (41)
Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. (1994) (40)
Nutritional requirements for infants with renal failure. (1986) (38)
Chronic kidney disease: mineral and bone disorder in children. (2013) (38)
Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis. (1989) (38)
Bone density measurements in pediatric patients with renal osteodystrophy (2003) (37)
Evaluation of hypophosphatemia: lessons from patients with genetic disorders. (2012) (37)
Psychological distress and treatment adherence among children on dialysis (1997) (36)
Sudden blindness caused by anterior ischemic optic neuropathy in 5 children on continuous peritoneal dialysis. (2003) (36)
Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function (2012) (36)
Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. (2012) (35)
Correlates of parathyroid hormone concentration in hemodialysis patients. (2013) (35)
FGF23 and mineral metabolism in the early post-renal transplantation period (2013) (34)
Peritonitis in children undergoing continuous ambulatory peritoneal dialysis. (1983) (34)
Hernias: a frequent complication in children treated with continuous peritoneal dialysis. (1987) (34)
Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease (2018) (33)
Are new vitamin D analogues in renal bone disease superior to calcitriol? (2005) (32)
Bone histology in steroid-treated children with non-azotemic nephrotic syndrome (2004) (31)
New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. (2002) (30)
Skeletal response to recombinant human growth hormone (rhGH) in children treated with long‐term corticosteroids (1995) (30)
Aluminum removal by peritoneal dialysis: intravenous vs. intraperitoneal deferoxamine. (1986) (30)
The therapeutic approach to the infant, child, and adolescent with end-stage renal disease. (1987) (30)
Report of an NIH task force on research priorities in chronic kidney disease in children (2005) (29)
Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients (2015) (29)
Racial–ethnic disparities in mortality and kidney transplant outcomes among pediatric dialysis patients (2017) (29)
Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis (2012) (28)
Outcome of Slipped Capital Femoral Epiphysis in Renal Osteodystrophy (2003) (28)
Antibacterial Responses by Peritoneal Macrophages Are Enhanced Following Vitamin D Supplementation (2014) (28)
Growth hormone and the skeleton in pediatric renal allograft recipients (2002) (28)
Infectious and catheter-related complications in pediatric patients treated with peritoneal dialysis at a single institution (2004) (27)
Continuous ambulatory peritoneal dialysis in pediatric patients: a 20-month experience. (1983) (27)
Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis. (2014) (27)
Longitudinal evaluation of transport kinetics in children receiving peritoneal dialysis (1999) (27)
Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. (2000) (27)
Continuous ambulatory peritoneal dialysis catheters in children. (1983) (26)
Oral and parenteral calcitriol for the management of end-stage renal disease. (1991) (26)
Comparison of continuous cycling peritoneal dialysis with continuous ambulatory peritoneal dialysis in children. (1984) (26)
Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol (2016) (26)
Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography (2013) (26)
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis (2005) (26)
Parathyroid gland function and the set point for PTH release: understanding the available data. (1996) (25)
Prevention of renal osteodystrophy in predialysis patients. (1999) (25)
Validation of PD Adequest 2.0 for pediatric dialysis patients (2001) (24)
The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial. (2013) (24)
Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy. (1991) (24)
Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? (2013) (24)
Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry. (2016) (24)
Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients (2015) (24)
Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease (1991) (23)
Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder (2017) (23)
Surgical aspects of dialysis in newborns and infants weighing less than ten kilograms. (2000) (23)
Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients (2010) (23)
Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism. (1997) (23)
VITAMIN D IN HEALTH AND DISEASE: Role of Parathyroid Hormone and Therapy with Active Vitamin D Sterols in Renal Osteodystrophy (2005) (23)
Non-invasive assessments of cardiovascular disease in patients with renal failure (2001) (22)
Non-renal-Related Mechanisms of FGF23 Pathophysiology (2018) (21)
Special aspects of renal osteodystrophy in children. (2004) (21)
Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease–mineral bone disorders (CKD-MBD) in children (2013) (20)
Bone and mineral metabolism in childhood end-stage renal disease. (1995) (20)
In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. (1996) (20)
Skeletal Consequences of Nephropathic Cystinosis (2018) (20)
Primary osteoblast-like cells from patients with end stage kidney disease reflext gene expression, proliferation and mineralization characteristics ex vivo (2014) (19)
Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism (2000) (19)
Altered diurnal regulation of blood ionized calcium and serum parathyroid hormone concentrations during parenteral nutrition. (2000) (19)
Impaired Growth, Delayed Ossification, and Reduced Osteoclastic Activity in the Growth Plate of Calcium-Supplemented Rats with Renal Failure. (2000) (19)
Experience with renal transplantation in children undergoing peritoneal dialysis (CAPD/CCPD). (1986) (19)
The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease (2010) (19)
Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation (2015) (19)
Intermittent Calcitriol Therapy and Growth in Children with Chronic Renal Failure (1998) (19)
Lipoproteins in Children Treated with Continuous Peritoneal Dialysis (1991) (18)
Tube feeding in children with end-stage renal disease. (1997) (18)
Purification and properties of peritoneal eosinophils from pediatric dialysis patients. (1990) (18)
Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol (2007) (18)
Renal Osteodystrophy in Children Undergoing Continuous Ambulatory Peritoneal Dialysis (1984) (17)
Effect of acute uremia on protein degradation and amino acid release in the rat hemicorpus. (1983) (17)
Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate) (2019) (17)
Managing phosphate retention: is a change necessary? (2000) (17)
Successful cadaveric renal transplantation in infants and young children. (1989) (17)
Selection of Peritoneal Dialysis for Pediatric Patients (1997) (16)
CAPD/CCPD in children: four years' experience. (1986) (16)
Prospective evaluation of aluminum loading from formula in infants with uremia. (1990) (16)
An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects (2012) (16)
Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone. (2019) (16)
Peritoneal kinetics in children undergoing continuous ambulatory/cycling peritoneal dialysis. (1987) (16)
Calcification of the coronary arteries in the absence of atherosclerotic plaque. (2005) (16)
The role of bone in CKD-mediated mineral and vascular disease (2015) (15)
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. (2017) (15)
Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model (2017) (15)
Leonardo da Vinci, Master Draftsman (2003) (15)
Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols (2009) (15)
Lack of FGF23 response to acute changes in serum calcium and PTH in humans. (2014) (15)
Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy. (2018) (15)
Features of renal osteodystrophy in pediatric patients receiving regular peritoneal dialysis. (1989) (14)
New PTH assays and renal osteodystrophy (2004) (14)
Chronic Kidney Disease Mineral and Bone Disorder (2012) (14)
Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient (2010) (13)
Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis. (2017) (13)
Tibial Physeal Changes in Renal Osteodystrophy: Lateral Blount's Disease (1992) (13)
Acquired cystic kidney disease in children undergoing long-term dialysis (2004) (13)
Cell biology of renal osteodystrophy (2002) (13)
Factors influencing the improvement in cadaveric renal transplant survival in pediatric recipients. (1989) (13)
Surgical correction of angular deformity of the knee in children with renal osteodystrophy. (1997) (12)
An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis (2018) (12)
CAPD and CCPD in children: an experience of 3 1/2 years (1984) (12)
Fibroblast growth factor 23: fueling the fire. (2016) (11)
Peritoneal dialysis workshop: pediatrics recommendations. (1997) (11)
Plasma exchange improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients (1987) (10)
Mineral bone disease in autosomal dominant polycystic kidney disease. (2020) (10)
Recent advances and controversies in childhood renal osteodystrophy (1987) (10)
CHAPTER 28 – Renal Osteodystrophy: Pathogenesis, Diagnosis, and Treatment (2003) (9)
4-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart; a feasibility study in children (2015) (9)
Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder? (2009) (9)
Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients (2018) (9)
PLASMA KINETICS OF INTRAVENOUS CALCITRIOL IN NORMAL AND DIALYSED SUBJECTS AND ACUTE EFFECT ON SERUM nPTH LEVELS. (1988) (9)
Cortical and trabecular bone in pediatric end-stage kidney disease (2015) (9)
Effect of vitamin B-6 deficiency on plasma amino acid levels in chronically azotemic rats. (1986) (9)
Peritonitis in Children Undergoing CAPD Versus CCPD (1985) (9)
Issues in pediatric dialysis. (1986) (8)
Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis (2018) (8)
Renal osteodystrophy in dialyzed children. (1991) (8)
Skeletal response to intermittent calcitriol therapy in secondary hyperparathyroidism. (1996) (8)
Lipoproteins in children treated with continuous peritoneal dialysis. (1991) (8)
The management of renal osteodystrophy (1996) (7)
Biochemical markers in metabolic bone disease (1994) (7)
Measurement of serum phosphate levels using a mobile sensor. (2020) (7)
Experience with continuous cycling peritoneal dialysis during the first year of life (1987) (7)
Magnetic resonance imaging of iron overload in children treated with peritoneal dialysis. (1988) (7)
Abnormal parathyroid gland function in CKD (2010) (7)
Enhanced muscle protein degradation and amino acid release from the hemicorpus of acutely uremic rats. (1984) (7)
The renal bone diseases in children treated with dialysis. (1996) (7)
Correspondence on “Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)” by Ferreira et al. (2021) (6)
Bone Canopies in Pediatric Renal Osteodystrophy (2016) (6)
Clinical research and training: an overview. (2002) (6)
[FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism]. (2011) (6)
CAPD/CCPD in Children: Update 1984 (1984) (6)
Correspondence on “Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)” by Ferreira et al. (2021) (6)
Aluminum toxicity complicating renal osteodystrophy. A case report. (1989) (5)
Postpartum renal failure in a patient with membranoproliferative glomerulonephritis type II. (1986) (5)
Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling (2021) (5)
BIOAVAILABILITY OF CALCITRIOL AFTER ORAL, INTRAVENOUS AND INTRAPERITIONEAL DOSES IN DIALYSIS PATIENTS. (1988) (5)
Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis (2018) (5)
Intravenous zoledronic acid (ZOL) compared to IV pamidronate (PAM) in children with severe osteogenesis imperfecta (OI) (2008) (5)
Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis (2000) (5)
Vitamin C overload may contribute to systemic oxalosis in children receiving dialysis (2020) (5)
Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD (2019) (5)
Bone disease in renal transplant recipients (2010) (5)
Recent advances in the management of renal osteodystrophy in children. (1993) (4)
Chronic kidney disease-mineral and bone disorder (CKD-MBD) in children (2010) (4)
Parathyroid gland function in secondary hyperparathyroidism (1996) (4)
Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. (2020) (4)
Ironing out the phosphorus problem. (2010) (4)
Racial differences in bone histomorphometry in children and young adults treated with dialysis. (2019) (4)
Race and Ethnicity Predict Bone Markers and Fracture in Pediatric Patients With Chronic Kidney Disease (2020) (4)
The set point revisited, again (1996) (4)
Serum albumin and hospitalization among pediatric patients with end-stage renal disease who started dialysis therapy (2019) (4)
Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists (2013) (4)
Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients (2019) (4)
Alport's syndrome and achalasia (1988) (4)
Treatment of severe hypercalcemia with peritoneal dialysis in an infant with end-stage renal disease (1988) (3)
Short-course antithymocyte globulin for treatment of renal transplant rejection in children. (1986) (3)
Vitamin D Therapy in Children on Dialysis (2007) (3)
A case report of Drash syndrome in a 46,XX female. (1991) (3)
Determination of FGF23 Levels for the Diagnosis of FGF23‐Mediated Hypophosphatemia (2022) (3)
Peritoneal clearances with different dialysis regimens in children undergoing continuous cycling peritoneal dialysis. (1989) (3)
Medical therapy in Chronic kidney disease (2010) (2)
Parathyroid Hormone-Immunoradiometric Assays as Noninvasive Predictors of Renal Osteodystrophy: The Need for Bone Histomorphometric Validation (2001) (2)
Unraveling the osteocyte in CKD-MBD post-renal transplantation. (2019) (2)
Growth plate disturbances in renal failure (2004) (2)
PATIENTS WITH SECONDARY HYPERPARATHYROIDISM (1999) (2)
The Accuracy of a Continuous Volumetric Balancing System in Pediatric Continuous Renal Replacement Therapy (2014) (2)
Nutritional factors and progression of chronic renal failure. (1986) (2)
Disodium ethylenediaminetetraacetate: adverse effects in dialyzed children (1993) (2)
Renal bone disease in pediatric patients receiving treatment with maintenance peritoneal dialysis. (1991) (2)
Lack of GNAS re-methylation during oogenesis may be a cause of sporadic pseudohypoparathyroidism type Ib (PHP1B). (2021) (2)
Consequences of Intermittent Calcitriol Therapy in Pediatric Patients with Secondary Hyperparathyroidism (1999) (2)
Optimal Management of Renal Osteodystrophy in Children Treated with CAPD and CCPD (1994) (2)
The nutritional approach for pediatric patients undergoing CAPD/CCPD. (1990) (2)
Chapters and Other Papers 1-6-2018 FGF 23 and Left Ventricular Hypertrophy in Children with CKD . (2019) (2)
Treatment of Renal Bone Disease (1979) (1)
Development of a translational research pathway at the David Geffen School of Medicine University of California, Los Angeles (2017) (1)
Current treatment options in secondary hyperparathyroidism. (2006) (1)
Peritoneal dialysis workshop (1997) (1)
1650 THE EFFECT OF CHRONIC CAPD/CCPD TREATMENT AND PERITONITIS ON PERITONEAL CLEARANCES IN PEDIATRIC PATIENTS (1985) (1)
Combining exercise and growth hormone therapy: how can we translate from animal models to chronic kidney disease children? (2016) (1)
Quantitative Computerized Tomography (QCT) versus Dual X-Ray Absorptiometry (DXA) in the Assessment of Bone Mineral Density of HIV-1 Infected Children (2012) (1)
Aluminum-Containing Phosphate Binding Agents and Plasma Aluminum Levels in Children Undergoing CAPD: Preliminary Results with the Use of Calcium Carbonate (1985) (1)
Mineral and Bone Disorders in Children with Chronic Kidney Disease (2015) (1)
CHAPTER 40 – Renal Bone Diseases: Clinical Features, Diagnosis, and Management (2001) (1)
Original article Hyperlipidemia in pediatric patients undergoing peritoneal dialysis (1988) (1)
The Optimal Dialysis Regimen for Children Undergoing Different Continuous Cycling Peritoneal Dialysis Protocols (1990) (1)
In vivo studies of parathyroid gland function in secondary hyperparathyroidism. (1996) (1)
Ask the expert (1990) (1)
Chapter 70 – Chronic Kidney Disease Mineral and Bone Disorder (2016) (1)
The Parathyroids in Renal Disease (2015) (1)
Correction: Bone Canopies in Pediatric Renal Osteodystrophy (2016) (1)
Diagnosis and Management of Renal Osteodystrophy in Children (2012) (1)
Evolution of Renal Osteodystrophy and the Effect of High-Dose Calcitriol in Children Undergoing CAPD (1985) (1)
The set point revisited, again. (1996) (1)
New Techniques in Paediatric Dialysis Treatment (1984) (1)
Nutritional Recommendations for Children Treated With CAPD/CCPD (1987) (1)
Redefining the pathogenesis of CKD-MBD: the critical role of FGF-23 (2010) (1)
FGF23 and inflammation, anemia, and iron (2021) (1)
Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium (2010) (1)
IPNA: Global Pediatric Nephrology, Introduction and Overview (2014) (1)
Pathophysiology and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (2018) (1)
Diagnosis and Treatment of Renal Bone Diseases in Children Undergoing CAPD/CCPD (1998) (1)
Skeletal Effects of Growth Hormone and Calcitriol in Children with ESRD (1999) (1)
ALUMINUM-RELATED HONE DISEASE AND SERUM ALUMINUM IN CHILDREN UNDERGOING CAPD (1984) (0)
"What Have You Been Judging From?": Subjectivity and Judgment in Jane Austen's Novels and George Eliot's Middlemarch (2011) (0)
Calcification and Its Treatment with Magnesium and Sodium Thiosulfate (2015) (0)
H. William Schnaper - Life course journey of a true Mensch (2021) (0)
339 DECREASED ANGIOGENESIS AND OSTEOCLASTOGENESIS IS ASSOCIATED WITH INCREASED TRABECULAR BONE VOLUME IN NEPHRECTOMIZED RATS GIVEN CALCIUM SUPPLEMENTATION (2005) (0)
In Memoriam: Jack W. Coburn, MD 1932-2004 (2004) (0)
Transcription factor HNF4α2 promotes osteogenesis and prevents bone abnormalities in mice with renal osteodystrophy. (2023) (0)
CHAPTER 93 – Nutritional Management of Children on Peritoneal Dialysis (2008) (0)
Listener Ratings of Male Singer Technical Ability. (2020) (0)
An ARHGAP25 variant links aberrant Rac1 function to early‐onset skeletal fragility (2021) (0)
[Children with chronic renal failure: evaluation of the nutritional status and management]. (1999) (0)
Review for "Inhibition of osteoclast differentiation by 1.25-D and the calcimimetic KP2326 reveals 1.25-D resistance in advanced CKD" (2020) (0)
Control of Renal Bone Disease by High-Dose Calcitriol and the Use of Calcium Carbonate as a Phosphate-Binding Agent in Children on CAPD/CCPD (1987) (0)
Erratum to "Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease" [Bone, 45(6) (2009) 1161-1168]. (2017) (0)
Response to “Elevated Fibroblast Growth Factor 23 and decreased Klotho levels are associated with diastolic dysfunction in CKD G4-5D patients” (2020) (0)
Bone marrow adiposity inversely correlates with bone turnover in pediatric renal osteodystrophy (2021) (0)
Chronic Kidney Disease (2021) (0)
Aluminium-related Bone Disease in Children with Renal Failure (1998) (0)
The Tenth Congress of the International Pediatric Nephrology Association (2004) (0)
The 12th Congress of the International Pediatric Nephrology Association (2001) (0)
daily hemodialysis is associated with lower plasma FGF 23 levels when compared with conventional hemodialysis (2014) (0)
The Authors Reply (2020) (0)
The Tenth Congress of the International Pediatric Nephrology Association (2004) (0)
Vitamin D in Children with Chronic Kidney Disease: A Focus on Longitudinal Bone Growth (2016) (0)
Author and Subject Index (1998) (0)
Pediatric Renal Osteodystrophy (1996) (0)
Response to ‘Osteodystrophy and dialysis survival’ (2007) (0)
PHOSPHATE WASTING AND FGF-23 KINETICS POST-RENAL TRANSPLANTATION.: 316 (2007) (0)
Response to ‘Osteodystrophy and dialysis survival’ (2007) (0)
A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial (2022) (0)
OP-NDTJ180322 2051..2088 (2019) (0)
Peritoneal Dialysis in Children: Issues for the 21St Century (1999) (0)
Chronic Kidney Disease (2011) (0)
Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna (2004) (0)
The Management of CKD-MBD in Pediatric Dialysis Patients (2021) (0)
Accumulation of Metals and Minerals in Chronic Kidney Disease (2005) (0)
Author response for "An ARHGAP25 variant links aberrant Rac1 function to early‐onset skeletal fragility" (2021) (0)
IMMUNOLOGICAL PARAMETERS AND INCIDENCE OF PERITONITIS IN CHILDREN ON CAPD (1984) (0)
Lost in Translation? (2008) (0)
18 Treatment of renal bone disease (2004) (0)
Nutritionalstatus of children undergoing continuousambulatory peritoneal dialysis13 (1983) (0)
LaudatioJoel D. Kopple (1998) (0)
Harriet Martineau and the Narrative Transmission of Social Knowledge (2019) (0)
Social Science and the Realist Novel’s Turn to Character (2018) (0)
Fantasies of Choosing in Rasselas (2015) (0)
Regional Variation in Bone Turnover at the Iliac Crest versus the Greater Trochanter. (2020) (0)
Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD (2021) (0)
An Animal Model To Evaluate Key Regulators of Endochondral Bone Growth in Renal Failure (1999) (0)
Racial Ethnic Differences in the Markers of Mineral and Bone Metabolism within the Pediatric Dialysis Population (2017) (0)
Title Idiopathic juvenile osteoporosis : a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography Permalink (2013) (0)
Osteodystrophy and dialysis survival. Authors' reply (2007) (0)
To “Write” a Wrong: The Unreliable Writer and The Trial of Narrative Form (2008) (0)
A 3 1/2 Year Experience with Peritonitis in Children Undergoing CAPD and CCPD (1986) (0)
Chronic Kidney Disease (2014) (0)
Review for "The CKD‐MBD syndrome: hysteresis in PTH involvement and PTH administration for its management" (2020) (0)
Ferumoxytol across the age spectrum: a single center experience of safety (2016) (0)
The vitamin D analog paricalcitol (Pc) upregulates osteocyte fibroblast growth factor 23 (FGF23) and improves the mineralization defect in experimental uremia (2011) (0)
Author response for "Race and ethnicity predict bone markers and fracture in pediatric patients with chronic kidney disease" (2020) (0)
4. Vitamin D in Chronic Kidney Disease: Current and Evolving Concepts (2011) (0)
Literature abstracts (1992) (0)
Bone remodeling compartment canopies in pediatric renal osteodystrophy (2014) (0)
Smartphone-based measurement of serum phosphate levels for patients with kidney disease (Conference Presentation) (2020) (0)
Dr. Ira Greifer (2015) (0)
FGF23-expressing osteocytes are confined to bone packets that completed primary mineralization in patients with chronic kidney disease on dialysis (CKD5D) (2019) (0)
Effects of Primary Kidney Disease Etiology on Renal Osteodystrophy in Pediatric Dialysis Patients (2022) (0)
PROGRESSION OF SECONDARY HYPERPARATHYROIDISM DESPITE ORAL CALCITRIOL THERAPY IN PEDIATRIC PATIENTS ON PERITONEAL DIALYSIS (CAPD/CCPD) (1991) (0)
[Effect of dietary protein content on growth, renal function and survival or uremic rats (proceedings)]. (1978) (0)
Plasma FGF23 is associated with left atrial remodeling in children on hemodialysis. (2022) (0)
Foreword (2005) (0)
Assessment of renal osteodystrophy using in situ hybridization in human growth plate cartilage (1999) (0)
316 PHOSPHATE WASTING AND FGF-23 KINETICS POST-RENAL TRANSPLANTATION. (2007) (0)
Third generation assay for PTH and bone histomorphometry in children on dialysis (2002) (0)
K/doqi Tm Disclaimer K/doqi Advisory Board Members K/doqi Tm Nutrition Work Group Membership Adult Work Group Members Pediatric Work Group Members Nkf-doqi Advisory Council* Nkf-doqi Steering Committee* Acronyms and Abbreviations List Abbreviation Term A1-ag A1-acid Glycoprotein Abw Ef Adjusted Edem (0)
Four Years Experience — CAPD and CCPD in Children (1987) (0)
The tenth congress of the International Pediatric Nephrology Association (2004) (0)
Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis (2020) (0)
1651 THE EFFECT OF DIALYSATE VOLUME ON PERITONEAL CLERANCES AND ON THE DEVELOPMENT OF HERNIAS IN CHILDREN TREATED WITH CAPD/CCPD (1985) (0)

This paper list is powered by the following services:

Other Resources About Isidro Salusky

en.wikipedia.org

What Schools Are Affiliated With Isidro Salusky?

Isidro Salusky is affiliated with the following schools:

Isidro Salusky's Academic­Influence.com Rankings